

Nationwide Trends in Management of Adult Myxopapillary Ependymoma

Daphne A Baracena BS ^{1*}, Arpine Khudanyan BS ^{1*}, Patrick D Kelly MD ², Claire Turina BA ¹, Jerry J Jaboin MD PhD ¹, Shearwood McClelland III MD ³

¹Department of Radiation Medicine, Oregon Health & Science University, Portland, OR; ²Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN; ³Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN



RARE-01

BACKGROUND

- Myxopapillary ependymomas (MPE) are WHO
 Grade I ependymomas that occur in the spine and
 have an annual incidence of 0.05-0.08 per
 100,000 people.
- Maximal, safe surgical resection is the recommended first line therapy.
- Due to the rarity of the disease there is a relatively poor understanding of the use of radiotherapy (RT) in the management of disease.

MATERIALS AND METHODS


 Using the National Cancer Database (NCDB), we analyzed the patterns and impact of RT on spinal MPE in adults diagnosed between 2002 and 2016.

RESULTS

- Of 753 qualifying cases, the majority of patients underwent resection (n = 617, 81.9%).
- A relatively small portion received RT (n = 103, 13.3%) with most receiving RT after surgical resection (n = 98, 95.1%).
- The likelihood of patients to undergo resection and RT was significantly associated with patient age at diagnosis (p = 0.002), tumor size (p < 0.001), and race (p = 0.017).
- Chemotherapy was not widely utilized (only 0.27% of patients).

Figure 1. Exclusion and Inclusion Criteria for NCDB Analyses of Adult MPE Patients

Figure 1. Exclusion and Inclusion Criteria for NCDB Analyses of Adult MPE Patients



RESULTS

Table 1A. Percent and P-Value of Adult MPE Patient Characteristics based on Receipt of Adjuvant RT.

	No Radiation Therapy		Radiation Therapy			P-	
	N	Column	Row %	N	Column	Row %	value
	IN	%	IXOW 70	IN	%	IXOW 70	value
Sex							0.91
Male	347	54.1%	86.5%	54	55.1%	13.5%	
Race							0.017
Caucasian	535	83.5%	87.3%	78	79.6%	12.7%	
Black	27	4.2%	93.1%	*	2.0%	6.9%	
Asian/Pacific	*	3.0%	100.0%	*	0.0%	0.0%	
Islander Hispanic/Latino	39	6.1%	73.6%	*	14.3%	26.4%	
Other	*	1.4%	81.8%	*	2.0%	18.2%	
Unknown	*	1.9%	85.7%	*	2.0%	14.3%	
Comorbidities							0.56
0	535	83.5%	86.2%	86	87.8%	13.8%	
1	78	12.2%	88.6%	*	10.2%	11.4%	
≥ 2	28	4.4%	93.3%	*	2.0%	6.7%	
Insurance							0.38
Not Insured	22	3.4%	81.5%	*	5.1%	18.5%	
Private Insurance	449	70.0%	87.4%	65	66.3%	12.6%	
Medicaid	59	9.2%	85.5%	*	10.2%	14.5%	
Medicare	90	14.0%	89.1%	*	11.2%	10.9%	
Other Government	*	1.7%	73.3%	*	4.1%	26.7%	
Unknown	*	1.6%	76.9%	*	3.1%	23.1%	
Education							0.58
≥ 13% High	245	38.3%	87.8%	34	34.7%	12.2%	
School Graduates	240	00.070	07.070	0-1	O-1.7 70	12.2/0	
Income							0.91
≥ 48K	424	66.3%	86.9%	64	65.3%	13.1%	
Population							0.54
Non-Metropolitan	91	14.2%	85.0%	*	16.3%	15.0%	
Metropolitan	536	83.6%	87.0%	80	81.6%	13.0%	
Unknown	*	2.2%	87.5%	*	2.0%	12.5%	0.40
Facility Type							0.18
Community Cancer Program	*	2.5%	84.2%	*	3.1%	15.8%	
Comprehensive							
Community	128	20.0%	93.4%	*	9.2%	6.6%	
Cancer Program	120	_0.070	JJ: 170		0.2 /0	310 /0	
Academic/Resear							
ch Program	171	26.7%	86.8%	26	26.5%	13.2%	
Integrated							
Network Cancer	60	9.4%	89.6%	*	7.1%	10.4%	
Program		31170	001070		/ 0	. 01170	
Unknown	266	41.5%	83.4%	53	54.1%	16.6%	
Facility Location	_50	/ 0	55		2 , 0	. 3.070	0.051
East/Atlantic	140	21.8%	94.0%	*	9.2%	6.0%	
Central	159	24.8%	85.9%	26	26.5%	14.1%	
West	76	11.9%	88.4%	*	10.2%	11.6%	
Other	266	41.5%	83.4%	53	54.1%	16.6%	
Extent of Surgery							
No Surgery	*	1.2%	64.3%	5	0.7%	35.7%	
Surgery	641	85.1%	86.7%	98	13.0%	13.3%	

Table 1B. Median and Range of Adult MPE Patient Characteristics based on Receipt of Adjuvant RT.

	No Radiation Therapy			Radiation Therapy			P- value
	N	Median	Range	N	Median	Range	
Age	641	44	33-56	98	36	26-52	0.002
Tumor size (mm)	448	23	15-40	63	39	20-64	< 0.001
Greater Circle distance (mi)	640	15.85	7.55- 37.2	98	16.25	6.3-39.7	0.83

* De-identified

RESULTS

Table 2. Adjuvant RT Administration in Adult MPE.

Extent of RT		V	Column %		
None	65	50	86.3%		
External Beam	8	9	11.8%		
SRS	*		0.1%		
	Median	Me	an	Standard Deviation	Range
RT Regional Dose (Gy)	50.4	48	.94	6.97	25-72
Radiation Ended (Days)	42	42.	.88	9.06	7-106
Number of RT to this Volume	28	28.	.87	4.92	5-56

CONCLUSIONS

- Given the high survival in this disease entity, the progression-free survival (PFS), an important outcome, is not available from this database even with the 15-year analysis of practice patterns.
- As expected, surgery is the primary means to manage adult MPE.
- For spinal MPE, gross total resection (GTR) is preferred when possible as studies have shown association of GTR with improved PFS.
- RT and chemotherapy are used infrequently. In univariate analyses, RT was employed more often for larger tumor sizes, Latino/Hispanic ethnicity, and younger age at diagnosis.
- The impact of RT on overall survival is indeterminate given the 1.6% death rate in the cohort.
- Analyses of the impact of RT on PFS in a larger database would be beneficial for determining an algorithm for post-operative and definitive radiotherapy in this disease entity.

DISCLOSURES

Baracena, Khudanyan, Kelly, Turina, Jaboin, McClelland – nothing to disclose

Corresponding Author: Jerry J Jaboin, MD, PhD. (jaboin@ohsu.edu)